French chemicals group Rhone-Poulenc, which controls the drugmaker Rhone-Poulenc Rorer, reports first nine months of 1994 sales at 63.4 billion French francs ($12.31 billion), a rise of 6.4% or up 5.5% on a comparable basis. Operating income improved 15.3% to 5.4 billion francs, with the best performance attributed to the chemicals and fibers divisions (up 223%) and also to agrochemicals, where operating income doubled in the nine months.
Results in the health care sector remained depressed, the company says, because of the significant provision undertaken by R-PR during the first half of the year (some 699 million francs). The sector's operating income (see also Marketletter October 31), however, before provisions for restructuring expenses and non-recurring items, rose marginally during the first three quarters due to stronger third-quarter results at R-PR and the sector's other businesses, the group reports.
On balance, the group's nine-month results are ahead of many analysts' expectations, and some of them have revised upwards their forecasts for the full year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze